

References

REFERENCES

- Ackerman, D.A.; Barry, J. M.; Wicklund, R.A.; Olson, N.(1993):**
Analysis of risk factors associated with prostate cancer extension to the surgical margins and pelvic node metastasis at radical prostatectomy.J. Urol., 150: 1845-1852.
- Andersson, S. O.; Baron, J.; Wolk, A.; Adami, H. O.(1995):**
Early life risk factors for prostate cancer. A population- based case control study in Sweden. Cancer Epidemiol. Biom. PREV., 4:187-192.
- Andriole, G.L.; Telle, W.B.; Coplen, D.E.; Catalona, W.A..((1992):**
PSA index as predictor of prostate cancer in men with persistent serum PSA elevation.J.Urol.,60: 599.
- Arnheim, F.K.(1948);**
Carcinoma of the prostate: A study of post-mortem findings in one hundred and seventy-six cases. J. Urol., 60: 599.
- Aron, M., Rajeev, T.P., Gupta, N.P.(2000):**
Antibiotic prophylaxis for transrectal needle biopsy of prostate: a randomized controlled study. B.J.U., 85: 682-685.
- Aus, G.; Ahlergn, G.; Bergdahl, S.; Hugosson, J.(1993):**
Infection after transrectal core biopsies of the prostate- risk factors and antibiotic prophylaxis.B.J.U.,71:457-459.
- Ayala, A. G.; Ro, J. Y.; Babian, R.(1989):**
The prostatic capsule : does it exists? Its importance in staging and treatment of prostatic carcinoma. Am. J. Surg. Path., 1: 21-72.
- Babaian, R.J., Toi, A. Kamoi, K. et al. (2000):**
A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J.Urol., 163:152-157.
- Bairati, I.; Meyer, F.; Yeves, F.; Moore, L.(1998):**
Dietary fat and advanced prostate cancer. J. Urol., 159: 1271-1275.
- Batson, O. V.(1940):**
The function of vertebral veins and their role in the spread of metastasis.Ann. Surg., 112: 138.

Bangama, C.H.; Rietbergen, J.B.; Kranse, R.; Blijenberg, B.G.; Pettersson, K., Schroder, F.H.(1997):
The free to total prostatic specific antigen ratio improves the specificity of prostatic specific antigen in screening for prostate cancer in general population. *J.Urol.*, 157:2191-2196.

Batson, O.V.(1964):
The function of vertebral veins and their role in the spread of metastasis. *Ann. Surg.*, 112: 138.

Bauer, J. J.; Sesterhenn, I. A.; Mostofi, F. K.; Moul, J. W.(1996):
Elevated levels of apoptosis regulator protein p 53 and bcl-2 are independent prognostic biomarkers in surgically treated , clinically localized prostate cancer. *J. Urol.*, 56:1511-1516.

Bazinet,M.; Karakiewicz ,P.I.;Aprikan,A.G.(1996):
Value of systematic transition zone biopsies in the early detection of prostate cancer.*J.Urol.*,155: 605-606.

Benson,M.C.;Olsson, C .A.(1989):
The staging and grading of prostatic cancer.In:Fitzpatrick, J.M.;Krane, R.J.(Eds).*The Prostate*. New York: Churchill Livingstone, pp:261.

Berthon ,P.; Valeri, A.; Cohen-Akenine, A.; Paiss,T.; Demenais,F.; Chumakov,I.; Bachnor, L.;Cussenot, O.(1998):
Predisposing gene for early – onset prostate cancer ,localized on chromosome 1q 42.2-43. *Am. J.Hum. Genet.*,62: 1416-1424.

Borboroglu, P.G.; Comer, S.W.; Riffenberg, R.H.(2000):
Extensive repeat TRUS guided biopsy of prostate in patients with previous benign sextant biopsies. *J.Urol.*, 163:158-162.

Botswick, D.G.;Brawer, M. K.(1967):
Prostate intraepithelial Neoplasia and early invasion in prostate cancer. *Cancer*, 59: 788-794.

Botswick,D.G.(1996 b):
Prostatic intraepithelial Neoplasia and atypical Adenomatous hyperplasia. *Cancer*, 78: 330-336.

Bothman, A. R.(1997):
Cytogenetic studies in prostate cancer :are we making progress? *Cancer Genet. Cytogenet.*, 95:116-121.

- Brawer, M.K.; Bigler, S.A.; Sohlberg, O. E.(1990):**
Significance of prostate intraepithelial Neoplasia on prostate needle biopsy. *Urol. Suppl.*, 38: 103-107.
- Bretton, P.R.; Evans, W.P.; Borden, J.C.; Castelan, R.D.(1994):**
The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma. *Cancer*, 74:2991.
- Burns, P.N.; Interpretation and analysis of Doppler signals. In: Taylor KJW, Burns PN, Wells PNT, eds.(1988):**
Clinical Application of Doppler Ultrasound. New York: Raven Press; 77.
- Candas, B.; Cusan, L.; Gomez, J.L.; Labrie, F.(2000):**
Evaluation of PSA and DRE as screening for prostate cancer. *Prostate*, 45(1): 19-35.
- Carruba, G.; Miceli, M. D.; Comito, L.; Castagnetta, L. A.(1996):**
Multiple estrogen function in human prostate cancer cells. *Annals N. Y. Acad. Sci.*, 78:70-84.
- Carter, B. S.; Bova, G. S.; Beaty, T. Y.; Walsh, P. C.(1993):**
Hereditary prostate cancer: epidemiology and clinical features. *J. Urol.*, 150:797-802.
- Carter, H.B.; Person, J.D.; Morrell, C.H.(1995):**
What is the shortest time over which PSA velocity should be measured (abst.)? *J. Urol.*, 53: 143A.
- Catalona, W. J.; Scott, W.W.(1986):**
Carcinoma of the prostate. In: Walsh, P.C.; Gittes, R.F.; Perlmutter, A.D.; Stamey, T.A.; eds. *Campbell Urology*. 5th Ed. Philadelphia: W B Saunders Co., pp: 1463.
- Catalona, W.J.; Smith, D.S.; Ratliff, T.L.(1991):**
Measurement of prostate specific antigen as screening test for prostate cancer. *N. Engl. J.*, 324: 1156.
- Catalona, W.J.; Smith, D.S.; Wolfert, R. L.(1995):**
Evaluation of percentage of free serum prostatic specific antigen to improve specificity of prostate cancer screening. *J.A.M.A.*, 274: 1214-1220.
- Cerhan, J. R.; Torner, J. C.; Lynch, C. H.; Wallace, R. B.(1997):**
Association of smoking, body mass and physical activity with risk of prostate cancer in the Iowa 65 Rural Health Study (US). *Cancer Causes Control*, 8:229-238.

- Chivers, R.C.; Parry, R.J. (1978):**
Ultrasonic velocity and attenuation in mammalian tissues. *J. Acoust. Soc.Am.*, 63: 40-953.
- Cho. J.Y.; Kim, S.H.; Lee, S.E.. (1998):**
Diffuse prostatic lesions: role of color Doppler and power Doppler ultrasonography. *J.Ultrasound Med.*, 17(5): 283-287.
- Clements, R. (2002):**
The role of transrectal ultrasound in diagnosing prostate cancer. *Curr. Urol. Rep.*, 3(3): 194-200.
- Clinton, S. K.; Emenhiser, C.; Schwartz, S. J.; Man, J. W.(1996):**
Cis- trans lycopene isomers, carotenoids, and retinol in the human prostate. *Cancer Epidemiol. Biol. PREV.*, 5: 823-833.
- Cohen, P. ; Peehl, D. M.; Stamey, T. A.(1993):**
Elevated level of insulin- like growth factor- binding protein-2 in the serum of prostate cancer patients. *J. Clin. Endocrinol. Metab.*, 76: 1031-1035.
- Coleman, M. P.; Esteve, J.; Damiecki, P.; Arslan, A.(1993):**
Trends in cancer incidence and mortality. I A R C Sci Pub No. 121. Lyon.
- Cooner, W.H.(1990):**
Anatomy of the prostate cancer as seen by ultrasound. *AUA Update Series*, 9:42.
- Cooney, K. A.; McCARTHY, J. D.; Lange, K.; (1997):**
Prostate cancer susceptibility locus on chromosome 19: a confirmatory study. *J. Natl. Cancer Inst.*, 89:955-959.
- Corder, E. M.; Chute, C. G.; Guess, H. E.; Beard, C. M.(1994):**
Prostate cancer in Rochester, Minnesota(USA), from 1935 to 1989: Increase incidence related to more complete ascertainment. *Cancer Causes Control*, 5: 207-214.
- Cosgrove D.O., Bamber J.C. and Davey J.B.: (1990):**
Color Doppler signals from breast tumors. *Radiology*, 176: 175.
- Crundwell MC, Cook and Wallace:(1999):**
Patient's tolerance of transrectal ultrasound-guided biopsy: An audit of 104 cases. *BJU* 83(7): 792-795,
- Culig, Z.; Hobeish, A.; Hittmar, A.; Klocker ,H.(1998):**
Expression ,structure and function of androgen receptor in advanced prostatic carcinoma. *Prostate*, 35: 63-70.

- Cunha, G. R.; Donjacours, A. A.;cOOKE, p. s.;Sugimura, Y.(1987):**
The endocrinology and developmental biology of the prostate.Endocrine Soc.,
8:338-362.
- Deliveliotis,C.; Alivizatos, G.;Stravropoulos, N.J.(1993):**
Influence of digital examination ,cystoscopy,transrectal ultrasonography and needle
biopsy on the concentration of prostate specific antigen.Urol.Int., 53: 186-190.
- Dodds,P. R.; Caride, V. I.; Lytton, B.(1981):**
The role vertebral veins in the dissemination of prostatic carcinoma. J. Urol, 126:
753.
- Edwards,C.N.; Steinhorsen, E.; Icholsoy, D.(1956):**
An autopsy study of latent prostate cancer. Cancer, 6: 531-534.
- ElGabry, E.A., Halpern E.G.; Strup, S.E.; Gomella L.G.(2001):**
Imaging prostate cancer: current and future applications. Oncology. 15(3):325-336.
- Ellis, W. G.; Vessela, R. L.; Buchler, K. R.; Lange, P. H.(1996):**
Charecterization of a novel androgen-sensitive, prostatic-specific-antigen-PSA-
producing prostatic carcinoma xenograft: Lu Ca p 23. Clin. Cancer Res., 2:1039-
1048.
- Ellis, L.;Nyborg, H.(1992):**
Racial / ethnic variations in male testosterone levels: A probable contribution to
group differences in health. Steroids, 57:72-75.
- Epstein, J.I.(1994):**
Prostatic intraepithelial neoplasia. Adv. Anat. Pathol., 1:123-134.
- Epstein, J.I.(1995):**
Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy.
Hum. Pathol., 26: 223-229.
- Ferdinandez, F.(2003):**
Contrast-enhanced ultrasound improves prostate cancer detection. Diagnostic
Imaging, 678:456-467.
- Ferro,M.A.; Barnes,I.;Roberts,J.B.M.;Smith,P.J.B.(1987):**
Tumor marker in prostatic carcinoma: A comparison of prostate specific antigen
and acid phosphatase.B.J.U.,60:69.

Flocks, R. H. (1973):

The arterial distribution within the prostatic gland : Its role in trans-urethral resection of prostate. *J. Urol.*, 37: 524.

Fong, I.W.; Struther, N.; Honey, R.I. (1976):

A randomized comparative study of the prophylactic use of trimethoprim-sulphamethoxazole versus netilmycin-metronidazole in transrectal prostatic biopsy. *J. Urol.*, 146:179.

Franco, O.E.; Arima, K.; Yanagawa, M.; Kawamura, J. (2000):

The usefulness of power Doppler ultrasonography for diagnosing prostate cancer: Histological correlation of each biopsy site. *B.J.U.*, 85:1049-1052.

Gann, P. H.; Hennekens, C. H.; Sacks, F. M. (1994):

Prospective study of plasma fatty acids and risk of prostate cancer. *J. Natl. Cancer Inst.*, 86:281-286

Gann, P. H.; Ma, J.; Hennekens, C. H.; Hollis, B. W. (1996):

Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. *Cancer Epidemiol. Biom. Prev.*, 5: 121-126.

Gann, P. H.; Hennekens, C. H.; Stampfer, M. J. (1996 b):

Prospective study of sex hormone levels and risk of prostate cancer. *J. Natl. Inst.*, 88: 1118-1126-

Gibbs, M.; Sanford, J. L.; McIndoe, R. A. (1999):

Evidence for a rare prostate carcinoma susceptibility locus at chromosome 1 p 36. *Am J. Hum. Genet.*, 64:776-787.

Gillenwater, J.Y. (2000):

Peri-prostatic local anesthesia before ultrasound guided prostate biopsy. *J. Urol.*, 163:173.

Giovannucci, E.; Ascherio, A.; Rimm, E. B. (1995):

Intake of carotenoids and retinol in relation to prostate cancer. *J. Natl. Cancer Inst.*, 87:1767-1776.

Goss, AS, Johnston RL, Dunn F. (1979):

Comprehensive compliance of empirical properties of mammalian tissues. *J Acoust. Soc. Am.* 1979; 64: 423-457.

Gleason, D.F.; Mellinger, G.T. (1974):

Urologic research group: Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. *J. Urol.*, 111:58.

- Goossen T, Wijkstra H. (2003):**
Transrectal US imaging and prostate cancer. Arch. Ital. Urol. Androl. 75(1): 68-74.
- Greenblatt, M. S.; Bennett, W.P; Hollstein, M.; Harris, C.C. (1994):**
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878.
- Gronberg,H.; Damber, L.; Damber. J. E.(1994):**
Studies of genetic factors in prostate cancer in twin population .J. Urol.,152: 1484-1487.
- Gronberg, H.; Isaacs, S. D.; Smith, J. R.; Isaacs W. B.(1997):**
Characterestics of prostate cancer in families potentially linked to hereditary prostate cancer HPCI locus. J.A.M.A., 278:1251-1255.
- Guess,H.A.;Heyse,J.F.;Gromley,G.J.(1993):**
The effect of fenasteride on prostate specific antigen in men with benign prostatic hyperplasia. Prostate,22:31-37.
- Hagood,P.G.; Parra,R.O.; Rauscher,J.A.(1994):**
Non-traumatic elevation of prostate specific antigen following cardiac surgery and extra corporeal cardio-pulmonary bypass.J.Urol.,152:2043.
- Halpern, E. J; Strup, S. (2000):**
Using gray-scale and color and power Doppler sonography to detect prostate cancer. Am. Roentegen Ray Sosciety, 65: 623-627.
- Halpern, E.J; Frauscher, F; Forsberg, F. (2002):**
High frequency Doppler ultrasound of the prostate: Effect of patient position. Radiology, 222(3): 634-638.
- Halpern, E.J; Frauscher, F; Strup, S. (2002):**
Prostate: High frequency Doppler US imaging for cancer detection. Radiology 222(1): 71-77.
- Hartman, T. J.; Albanes , D.; Tangrea, J. A.; Taylor, P. R.(1998):**
The association between baseline vitamin E, selenium and prostate cancer in the alpha- tocopherol, beta carotene cancer prevention study. Cancer Epidemiol. Biom. Prev., 7: 335-340.
- Hayes, R. B.; Zeiger, R.G.; Gridley, G.; Hoover, R. N.(1999):**
Dietary factors and risks for prostate cancer among blacks and whites in the U SA. Cancer Epidemiol. Biom. Prev., 8:25-34.

- Heinonen, O. P.; Albanes, D.; Virtamo, J.; Taylor, P. R.(1998):**
Prostate cancer and supplementation with alpha- tocopherol and beta- carotene: incidence and mortality in a controlled trial. J. Natl. Cancer Inst., 90: 440-446.
- Herchman,D.; Smith,D.; Catalona,W.J.(1996):**
Effect of ejaculation on free and total PSA levels. J. Urol.,155:433A:
- Hodge, K.K.; Mc Neal, J.E.; Stamey, T.A.(1989):**
Ultrasound guided TRUS of the palpably abnormal prostate. J.Urol., 142: 66-70.
- Hoskins, P.R.(1990):**
Measurement of arterial blood flow by Doppler Ultrasound. Clinical Physics and Physiological Measurement, 11:1-26.
- Hsing, A. W.; Mc Laughlin, J. K.; Zheng, W.(1994):**
Occupation, physical activity and risk of prostate cancer in Shanghai, China.Cancer Causes Control ,5: 136-140.
- Hytinen, E. R.; Thalmann, G. N.; Zhau, H.E.;Visakoppi, T.(1997):**
Genetic changes associated with acquisition of androgen independent growth, tumorigenicity and metastatic potential in a prostate cancer model. Br.J.Cancer, 75:190-195.
- Ismail, M: Gomella, G. (2002):**
Ultrasound for prostate imaging and biopsy. Curr. Opin. Urol., 11(5): 471-477.
- Issa,M.M.; Bux, S.; Chun, T.(2000):**
A randomized prospective trial of intra-rectal lidocaine for pain control during transrectal prostate biopsy: The Emory University experience. J.Urol., 164: 387-399.
- Ito, K.; Kupota, Y.; Yamamoto, T.; Suzuki, T.: Kurukawa, I. (2001):**
Long-term follow up of mass screening for prostate carcinoma in men with initial PSA-level 4 ngm/ml or less. Cancer, 91(4): 744-751.
- Ito, K.; Kamoi, K: Yokohama, K.; Yamada, K.; Nishimura, T. (2003):**
Visualisation of prostate cancer using dynamic contrast-enhanced MRI: Comparison with transrectal power Doppler US. Br. J. Radiol.; 76(909): 617-724.
- Jacobs,S.C.(1983):**
Spread of prostatic cancer to bone. Urology, 21: 337.
- Kaplan, S.S.; Te,A.E.;Pressler, L.B.;Olsson, C.A.(1995):**

Transitional zone index as a method of assessing benign prostatic hyperplasia: correlation with symptoms ,urine flow and detrusor pressure .J.Urol., 154: 1764-1769.

Kanety ,H.; Madgar, Y.; Dagan, Y.(1993):

Serum IGFBP2 is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum PSA. J. Clin. Endocrinol. Metab., 77: 229-233.

Kasper, S.; Sheppard, P. C.; Yan,Y.; Matusik, R. J.(1998):

Development, progression and androgen dependence of prostate tumors in probasin- large T cell antigen transgenic mice: a model for prostate cancer. Lab. Invest., 78(3):319-333.

Kasai ,C.; Namekawa, K.; Koyano, A. (1985):

real time two dimensional blood flow imaging using an auto-correlation technique. Institute of Electrical and Electronics Engineers Transactions in Sonography and Ultrasonography, 32: 458-464.

Kaul, L.; Heshmat, M. Y.; Kovi, J.; Jackson, M. A.(1987):

The role of diet in prostate cancer . Nutr. Cancer, 9: 123-128.

Kaye, K. W.;Horwitz, C.A. (1989):

Transrectal ultrasound guided biopsy. Urology, 31:19-26.

Kaye,K.W.; Reichter, U.(1999):

Ultrasonographic anatomy of normal prostate gland: Reconstruction by computer graphics. Urology, 35: 12.

Kaye, K. W.; (1991):

Ultrasound of normal prostate. Contemp. Urol., 3: 64-69.

Keener, T.; Winter, T.; Berger,R.; Krieger, J; Nodell, C.; Rothman, J.; Ngheim, H.(2000):

Prostate vascular flow: The effect of ejaculation on prostate vascular flow revealed on transrectal power Doppler sonography. A.J.R., 175:1169-1171.

Kelly, I.M.G.; Lees, W.R.; Rickards, D.(1993):

Prostate cancer; The role of color Doppler US. Radiology, 189:153.

Key, T, J.; Sloocks, P. B.; Davey, G. K.(1997):

A case control study of diet and prostate cancer. Br. J. Cancer, 76: 678-687.

Klausser, A.; Frauscher, F.; Halpren, E.J.; Horniner, W,; Bartsch, G.(2003):

Detection of prostate cancer with a microbubble ultrasound contrast agent. Lancet, 357(927):1849-1850.

- Klocker, H.; Culig, Z.;Hobisch, A.;Cato, A. C.(1994):**
Androgen receptor alterations in prostate carcinoma. *Prostate*, 25:266-273.
- Kostev, R.; Kolev, N.; Stratev,S.; Mikhailov, O. (2000):**
Local screening programme for prostate cancer. *Khirurgiia (Sofia)*: 56(5-7): 52-54.
- Krain , L. S.(1984):**
Some epidemiological variables in prostatic carcinoma. *Pre. Med.*, 3:154-159.
- Kremakau F.W(1992)::**
Doppler priciples. *Seminars of Rontegnology*, 27: 6.
- Kucers, A.; Crowe, S.M.; Gryson, M.L.; Hoy, J.F.(1997):**
Tinidazole In the use of anti biotics: A clinical review of antibacterial, antifungal and antiviral. Fifth ed. Oxford: Butterwoth, Heinemaran: 959-964.
- Labrie, F.; Candas, B.; Dupont, A.; Cusan, L.; Gomez, I.L.; Belanger, A.(1999):**
Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. *Prostate*, 140(2): 130-134.
- Lalani, E. N.;Laniado, M. E.; Abei, P. D.(1997):**
Molecular and cellular biology of prostate cancer.*Metastasis Research*, 16: 29-66.
- Landis, S.H.; Murray, T.;Bolden, S.;Wingo, P. A.(1999):**
Cancer statistics,1999. *CA Cancer J Clin.*,9:8-31.
- Landstorm, M.;Zhang, J.X.;Hallmans, G.(1998):**
Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats. *Prostate*, 36:151-161.
- La Vecchia, C.; Fraceschi, S.; Talamini, R.; D'avanzo, B. (1993):**
Marietal status indicators of sexual activity and prostate cancer. *J. Epidemiol Community health*, 47:450-453.
- Laviopierre, G.J.; Snow, R.M.; Frydenberg, M.; Gunter, D.; Reisner, G.; Royce, P.L.; Laviopierre,a.m.(1998):**
Prostate cancer : role of color Doppler imaging in transrectal sonography. *A.J.R.*, 171:205-210.
- Lee, F.(1989):**
Transrectal ultrasound: Diagnosis and staging of prostatic cancer.*Urol.*, 33(suppl.)5.
- Lengauer, C.; Kinzler, K. W.; Voglestein, B.(1998):**
Genetics instabilities in human cancer. *Nature*, 396:643-649.

- Lentle, B. C.; McGowan, D.G.; Dierich, H.(1974):**
Technetium-99 Mpolyphosphate bone scanning in carcinoma of the prostate. BJU., 46: 543.
- Lesko, S. M.; Rosenberg, L.; Shapiro, S.(1996):**
Family history and prostate cancer risk. Am. J. Epidemiol., 144:1041-104
- Levi F. ;Vecchia ,C.; Randinbison ,L.;Erler,G.;Franceschi,S.(1998):**
Incidence, mortality and survival from prstate cancer in Vaud and Neuchatel Switzerland. Ann. Oncol., 31-35.
- Lilja,H.(1993):**
Structure, function and regulation of the enzyme activity of prostate specific antigen. World J. Urol., 11: 188.
- Lowsly O. S.(1982):**
The development of the human prostate gland with reference to the development of other structures at the neck of the urinary bladder. Am. J. Anat., 13: 299-203.
- Macintosh, C. A.; Stower, M.; Reid, N.; Maitland , N. J.(1998):**
Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res., 58:23-28.
- Mann ,W.J.; Pick, A.; Shreiber, J.; Maurer, J.; Amedee, R.J.; Gluckmann, J.L.(1994):**
Ultrasonography for evaluation of the carotide artery in head and neck cancers. Laryngoscope, 104: 885-888.
- Maraji, b.h.; wheeler, P.; Markham, A.F.(1998):**
Prostatic specific membranous antigen.Br. J. Urol., 81: 523-528.
- Maroulakou, I. G.; Anver, M.; Garrett, L.; Green, J. E.(1994):**
Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian 40 large tumour antigen fusion genes. Proc. Natl. Acad. Sci.U S A., 91:11236-11240.
- Mc Dicken ,W.N.(1991):**
Diagnostic Ultrasonics: Principles and Use of Instruments. London: Churchill Livingstone., 12: 375-384.
- Mc Neal,J. E.(1968):**
Regional morphology and pathology of the prostate. Am. J. Clin.Pathol., 49: 347.
- Mc Neal, J. E.(1972):**
The prostatic urethra: a morphologic synthesis. J. Urol., 107: 1008-1011

- Mc Neal, J. E. (1978):**
Origin and evolution of benign prostatic hyperplasia .Invest. Urol., 15: 340-342.
- Mc Neal, J. E. (1984):**
Anatomy of the prostate and morphogenesis of BPH. Prog. Clin. Biol. Res., 145:27-31.
- McNeal, J.E.;Bostwick, D.G.(1986):**
Intraductal dysplasia: A Premalignant lesion of the prostate. Hum. Pathol., 17: 64-71.
- McNeal, J. E.(1988):**
Normal anatomy of prostate and changes in benign prostatic hyperplasia and carcinoma. Sem . Ultras. CT. MR., 9: 329-344.
- Merritt CRB, Hykes DL, Hedrick W.R (1991):**
Medical diagnostic ultrasound instrumentation and clinical interpretation. Topics in Radiology and Council Report. JAMA 1991; 265: 1155-1159.
- Merritt CRP. Doppler Ultrasound:**
The basics Radio-Graphics 1991; 11: 109-119.
- Meyers ,R. P.; Geollner, J. R.; Cahill,D. R.(1987):**
Prostate shape, external striated urethral sphincter and radical prostatectomy: The apical dissection. J. Urol., 138:543-550.
- Meyer, F.;Bairati, I.; Fradet, Y.; Moore, L.(1997):**
Dietary energy and nutrients in relation to preclinical prostate cancer. Nutr. cancer, 29:120-129.
- Miller, G. J.;Cygan, J. M.(1994):**
Morphplogy of prostate cancer: The effects of multifocality on histological grading, tumor volume and capsule penetration. J. Urol., 152: 1709-1712.
- Mostofi, F.K.(1976):**
Problems of grading carcinoma of prostate. Seminars Oncol,3:161.
- Mostofi, F. K. (1980):**
Histopathological typing of prostate tumors. In: Mostofi, F.K.,ed. International Histological Classification of Tumors No,22. Geneva:WHO.
- Murphy, W. N.;Dean, P.J.;Brasfield, J. A. Tatum, L.(1986):**
Incidental carcinoma of prostate. Am. J. Surg. Path. ,10:170-174

- Navone, N. M.; Troncoso, P.; Pisters, L. L.; Conti, C. J.(1993):**
P53 protein accumulation and gene mutation in the progression of human prostate carcinoma. *J. Natl. Inst.*, 85:1657-1669.
- Navone, N. M.; Olive, M.; Ozen, M.; Davis, R.(1997):**
Establishment of two human prostate cancer cell lines derived from a single bone metastasis. *Clin. Cancer Res.*,3:2493-2500.
- Neal, D.E.J.; Clejan, S.; Sarma, L.(1997):**
Prostate specific antigen and prostatitis: Effect of prostatitis on serum PSA in the human and non human primate.
- Nelson, T.R.; Pretorius, D.H. (1988):**
The Doppler signal: where does it come from and what does it mean? *A.J.R.*, 151:439-442.
- Newman, J.S.; Bree, L.; Holmberg, L.(1995):**
Prostate cancer: diagnosis with color Doppler sonography with histologic correlation with each biopsy site. *Radiology*, 195:86-91.
- Oesterling, J.E.; Rice, D.C.; Glenski, W.J.(1992):**
Effects of cystoscopy, prostate biopsy and transurethral resection on serum PSA concentration. *Urology*, 42:273-276.
- Okihara, K.; Kojima, M.; Naya, Y.; Iida, A.; Watanabe, M.; Watanabe, H.(1979):**
Ultrasonic power Doppler imaging for prostate cancer: A preliminary report. *Tohoku J. Exp. Med.*, 182: 277-281.
- Okihara, K.; Kojima, M.; Nakanoushi, T.; Okada, K.; Miki, T.(2000):**
Transrectal power Doppler in the detection of prostate cancer. *B.J.U.*, 85: 1053-1057.
- Okihara, K.; Ukimera, O.; Mizutani, Y.(2003):**
Prostate cancer detection using power Doppler imaging. *Drugs Today*, 39(6): 389-398.
- Olsen, B.S.; Carlisle, R.W.(1970):**
Adenocarcinoma of the prostate simulating primary rectal malignancy. *Cancer*, 25:219.
- Optenberg, S.A.; Thompson, I.M.(1990):**
Economics of screening for carcinoma of the prostate. *Urol. Clin. North Am.*, 17:7719.

- Oyen, R. H.(1994):**
Contemporary imaging of the prostate.In. Petrovich / Baert (eds): Benign prostatic hyperplasia. Springer Verlag Berlin Heidelberg .pp 78-139.
- Partin, A. W.; Kattan, M.W.; Subong, E. N. (1997):**
Combination of prostate specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. A multi- institutional update. J.A.M.A., 277: 1445-1451.
- Paschka, A. G.; Buttler, R.; Young, C. Y.(1998):**
Induction of apoptosis in prostate cancer cell lines by green tea components, epigallo catechin -3-gallate. Cancer. Let., 130:1-7.
- Patel, U.; Richards, J. (1994):**
The diagnostic value of color Dopler flow in the peripheral zone of the prostate with histologic correlation. B.J.U., 74:590-595.
- Pattyn,G; Meeus,L.; Vandevoode, P.;Stegart, L.;Devos, V.;Casselmann, J.;rigauts, T.(1996):**
Departement of radiology. St Jan Hospital, Brugge, Belgium.
- PeterS, J.L.; Thompson, A.C., Mc Nicholas, T.A., Hines, J.E.W., Hanbury, D.C., Boustead, G.B.(2001):**
Increased patient satisfaction from transrectal ultrasonography and biopsy under sedation. B.J.U., 87: 827-830.
- Peterson, R.O.(1986):**
Prostate In: Peterson, R.O.,ED.Urologic Pathology. Philadelphia: J.B.Lippincott Co.,pp 589.
- Platz, E. A. ; Yeole, B. B.; Jussawalla, D.J.(1997):**
Vasectomy and prostate cancer :A case- control study in India.Int. J. Epidemiol., 26: 933-938.
- Potosky, A. L. ;Miller, B. A.; Albertsen, P. C.; Kramer, B. S. (1995):**
The role of increasing detection in the rising incidence of prostate cancer. J.A.M.A.,273:548-552.
- Purohit, R.S.; Shinohara, K.; Meng, M.V.(2003):**
Imaging of clinically localized prostate cancer. Urol.Clin.North Am.30(20):279-293.
- Rajah, R.; Valentinis, B.; Cohen, P.(1997):**

Insulin – like growth factor IGF- binding protein-3 induces apoptosis and mediates the effects of transforming growth factor – β –1 on programmed cell death through a p-53- and IGF independent mechanism. J. Biol. Chem., 272:12181-12188

Recker,F.;Kwiatkowski,M.K.;Piironen,T.;Pettersson, K.;Goepel,M.; Tscholl,R.(1998):
Free to total PSA ratio improves the specificity for detection of prostate cancer in patients with prostatism and intermediate PSA levels.B.J.U.,81:532-538.

Redman, J. F.(1996):
Anatomy of the genitourinary system. Gillenwater, J. Y.; Grayhack, J. T. ; Howards, S. S.; Duckett,J. W. Eds.In. Adult and paediatric urology, 3rd ed. St Louis, Mosby. Year Book Inc., pp:1-62.

Rees, M. A.; Mc Hugh T.A.; Dorr, R.D.(1995):
Assesment of bone scan, CT scan and lymph node dissection in staging patients with newly diagnosed prostate cancer, J. Urol., 153: 352A, Abstract 495.

Reichman, M. E. ;Hayes, R. B.; Zeigler, R. G.; Taylor, P. R.(1990):
Serum vitamin A and subsequent development of prostate cancer in the first national health examination survey epidemiologic follow up study. Cancer RES., 50:2311-2315.

Reissigl,A.; Klocker,H.; Pointener,J.(1996):
Usefulness of free/total PSA levels in prostate cancer screening.Urol.,48:62-66.

Resnick, M. I.(1990):
Normal sonographic anatomy of the prostate. I N: Resnick,M. I. (Eds). Prostatic Ultrasonography. Philadelphia: B .C. Decker Inc., pp:41.

Rifkin, M.D.; Mc Glynn, E.T.; Choi, H.(1990):
Echogenecity of prostate cancer correlated with histologic grade and stromal fibrosis. Radiology, 170:549-552.

Rifkin, M.D, Sudakoff S, Alexander AA.(1993):
Prostate : technique, results and potential applications of color Doppler US-scanning. Radiology 1993; 186: 509-13.

Ross, R. F.; Bernstein, L.; Lobo, R. A.;Hendersen, B. E.(1992):
5-alpha reductase activity and risk of prostate cancer among Japanese and U S white and black males. Lancet, 339:887-889.

Roy C, Buxy X, Lang H.(2003):
Contrast enhanced color Doppler endorectal sonography of the prostate: efficiency of detection of peripheral zone tumors and role of biopsy. I.Urol, 170:69-73.

- Rubin, J.M.; Bude, R.O.; Carson, P.L. (1994):**
Power Doppler US: a potentially useful alternative to mean frequency-based color Doppler US. *Radiology*, 190: 853-856.
- Saito, S. (2002):**
Evaluation of transrectal power Doppler US and effect of contrast-enhancement for detecting prostate cancer. *Nippon Hinyokika Gakkai Zasshi*, 93(4): 562-567.
- Sakarya, M.E.; Arslan, H.; Unal, O.; Atilla, M.K.; Aydin, S. (1998):**
The role of power Doppler US in the diagnosis of prostate cancer. *B.J.U.*; 82:386-388.
- Salo, J.O.; Ranniko, S.; Makinen, J.; Lehtonen, T.(1987):**
Echogenic structure of prostatic cancer imaged on radical prostatectomy specimens. *Prostate*, 10:1-5.
- Schroder, F.H.; Hermanek, P.; Denis, L.; Fair, W.R.; Gospodarowicz, M.K.; Pavone-Macaluso, M.(1992):**
The TNM classification of prostate cancer. *Prostate*, 4(suppl.):129.
- Sedelaar, J.P.; Vijvelberg, P.L.; De Reijeki, T.M.; De La Rosette, J.J.; Kil, P.G.; Brackeman, J.G.; Hendrix, P.J.(2001):**
Transrectal ultrasonound in the diagnosis of prostate cancer : : state of the art and prospectives. *Eur. Urol.*, 40(3): 275-284.
- Semijonow, A.; Roth, S.; Hamm, M.(1995):**
Non traumatic elevation of prostate specific antigen following cardiac surgery and extra corporeal cardio pulmonary bypass. *J.Urol.*, 155:295.
- Shibata, M. A.; Jorreyk, C. L.; Liu, M. L.; Green, J. E.(1998):**
The C3(1) /SV40 T antigen transgenic mouse model of prostate and mammary cancer. *Toxicol. Pathol.*, 26:177-182.
- Shigeno, K.; Igawa, M.; Shina, H, H.; Wada, H.; Yoneda, T, T. (2000):**
The role of color Doppler US in detecting prostate cancer. *B.J.U.*, 86:229-233.
- Shinohara, K.; Wheeler, T.M.; Scardino, P.T.(1989):**
The appearance of prostate cancer in transrectal ultrasonography: Correlation of imaging and pathological examination. *J.Urol.*, 142: 76.
- Simone, N. L.; Bonner, R. F.; Gillespie, J. W.; Liotta, L. A.(1998):**

Laser – capture microdissection: opening the microscopic frontier to molecular analysis. *Trends Genet.*, 14:272-276.

Smith, D.S.; Catalona, W.J. (1995):

Inter examiner variability of digital rectal examination in detecting prostate cancer. *Urology*, 45:70-74.

Smith, J. R.; Carpten, J. D.; Gronberg, H.; Isaacs, W. B. (1996):

Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome – wide research. *Science*, 274:1371-1374.

Soloway, M.S. and Obek, C. (2000):

Peri prostatic local anaesthesia before ultrasound-guided prostate biopsy. *J.Urol.*, 163: 172-174.

Spiro, L.H.; Labay, G.; Irkin, L.A. (1974):

Prostatic infarction: Role in acute retention. *Urol.*, 3:345.

Stamey, T.A. (1995):

Making the most of systematic sextant biopsies. *Urol.*, 45: 2-12.

Stamey, T.A.; Yand, N.; Hay, A.R.; Mc Neal, J.E.; Freiha, F.; Redwine, E.A. (1987):

Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. *N. Engl. J. Med.*, 317:909.

Stanford, J.L.; Wicklund, K.G. Brawer, M.K. (1999):

Vasectomy and risk of prostate cancer. *Cancer Epidemiol. Biom Prev.*, 8:881-886.

Stearns, M.E.; Ware, J.L.; Agus, D.B.; Thalmann, G.N. (1998):

Workgroup 2: Human xenograft models of prostate cancer. *Prostate*, 36:56-58.

Stenman, U.H.; Leinon, J. Alfthan, H.; Ranniko, S.; Tuhkanen, K. (1991):

A complex between prostate specific antigen and alpha –1- anti chymotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. *Cancer Res.*, 51: 222-226.

Straussberg, R.L.; Dahi, W. P.; Klausener, R. D. (1997):

New opportunities for uncovering the molecular basis of cancer. *Natl. Genet.*, 15:415-416

Stoubakis, N.; Cookson, M.S.; Reuter, V.E. (1997):

Clinical significance of repeat sextant biopsies in prostate cancer patients. *Urol.*, 49(34): 113-118.

Srigly, J. R. (1988):

Small- acinar patterns in the prostate gland with emphasis on atypical Adenomatous hyperplasia and small –acinar carcinoma. *Semin. Diag. Pathol.*, 5: 524.

Schroder, F.H.(1997):

The free to total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in general population. *J.Urol.*, 157:2191-2196.

Tang, J.; Li, S.; Li, J.(2003):

Correlation between prostate cancer grade and vascularity on color Doppler imaging : preliminary findings. *J.Clin.ultrasound*, 31(2): 61-68.

Taylor, K.J.W.; Burns, P.N.; Wells, P.N.T.(1988):

Clinical application of Doppler ultrasound. New York: Raven Press. 3: 23-28.

Terris, M.K. (1997):

Transrectal ultrasound guided drainage of prostatic cyst. *J. Urol.*, 158: 179-180.

Tornblom, M.; Norming, U.; Adolfsson, J.; Becker, C.; Abrahamsson, P.A.; Lilja, H.; Gustafsson, O.(1999):

Diagnostic value of percent free PSA: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3ngm/ml. *Urology*, 53(5): 945-950.

Tornblom, M.; Eriksson, H.; Franzen, S.; Gustafsson, O.; Hugosso, N.J.(2004):

Lead time associated with screening for prostate cancer. *Int. J. Cancer.*, 108:122-129.

Thompson, I.M.; Rounder, J.B.; Teague, J.L.(1987):

Impact of routine screening for adenocarcinoma of the prostate on stage distribution. *J.Urol.*, 137: 424-426.

Uozumi, J.; Tokuda, Y.; Fujiyama, C.; Takagi, N.; Meiri, H.; Kuratomi, K.; Nakamura, K.; Ichigi, Y.; Kinoshita, N.(2002):

Annual PSA tests are not necessary for men with a PSA level below 2 ngm/ml; Findings of prostate cancer screening programme. *Int.J.Urol.*, 9(6): 334-339.

Uzzo, R.G.; Wei, J.T., Waldbaum, R.S.(1995):

The influence of prostate size on cancer detection. *Urol.*, 46: 831-836.

Van Alewijk, D.C.; Van Der Weiden, M.M.; Eussen, B.J.; Trapman, J.(1999):

Identification of homozygous deletion at 8 p 12- 21 in a human prostate cancer xenograft. *Genes Chromosomes Cancer*, 24:119-126.

- Vandenberg, C. ; Guan, X. Y.; Von hoff, D.; Hearth, J.(1995):**
D N A sequence amplification in human prostate cancer identification by chromosome microdissection: potential prognostic implications. Clin. Cancer Res., 1: 11-18.
- Van Weerden, W. M.; De Ridder, C. M.; Verdaasdonk, C. L.(1996):**
Development of seven new human prostate tumor xenograft models and their histopathological charecterization. Am. J. Pathol., 149:1055-1062.
- Wainestein, M. A.; Robinson, D.; Kursh, E. D.(1994):**
CWR22: androgen- dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res., 54:6049-6052.
- Waisman, J.(1988):**
Pathology of neoplasms of the prostate gland. In: Skinner, D.G. and Lieskovsky G., eds. Diagnosis and management of genitourinary cancer. Philadelphia: WB Saunders Co., pp: 150.
- Wang, Y.; Hetson, W.; Fair, W.(1995):**
Soy isoflavones decrease the high- fat promoted growth of human prostate cancer- results of in vitro and animal studies. J. Cell Biochem. Suppl. ,22: 181-187.
- Wells P.N. (1988):**
Basic priciples and Doppler physics. In: Taylor KJ, Burns PN and WellsPN (Eds). Clinical application of Doppler US. New York: Raven Press. P.1,1988.
- Werahera, P. N.; Miller, G. J.; Taylor, G. D. (1995):**
A 3D reconstruction algorithm for interpretation and extrapolation of planar cross sectional data. I. E.E.E. Trans. Med. Image, 14: 765-772.
- Wheeler, T. M.(1989):**
Anatomic considerations in carcinoma of the prostate. Urol. Clin. North Amer., 16: 632-641.
- Whittmore, W. F.Jr.; Catalona, W.G.; Grayhack, J. T.; Hank, G.; Peters, P. C.; Shipley, W. U.; Walsh, P.C.(1988):**
Organ system program staging classification for prostate cancer. In: Coffey, D. S.; Resnick, M. I.; Dorr, F. A.; Karr, J. P., EDS. A multidisciplinary analysis of controversies in the management of prostate cancer. New York: Plenum Press, pp: 344.
- Whittmore, A. S.; Kolone, L. N.; Wu, A. H.; John, E. M.(1995):**
Prostate cancer in relation to diet, physical activity, and body size in blacks, whites and Asian in U S and Canada. J. Natl. Cancer Inst., 87:652-691.

White DN (1982):

Johann Christian Doppler and his effect- a brief history. *Ultrasound Medicine and Biology* 8: 583-591.

Willet, W. C.; Hunter, D. J.(1994):

Vitamin A and cancers of breast , large intestine and prostate: epidemiologic evidence. *Nutr. Rev.*, 52:s53-s59.

Wilson,C.S.;Dahl, D.S.; Middleton, R.G.(1977):

Pelvic lymphadenectomy for the staging of apparently localized prostate cancer.*J.Urol.*,117:197.

Wells P.N. (Eds.) (1989):

Clinical applications of Doppler ultrasound. New York: Raven Press, p. 1.

Yamamoto T, Ito K, Ohi M, Yamomka H.

Diagnostic significance of DRE and TRUS in men with PSA levels of 4 ng/ml or less. *Urology* 2001; 58(6): 994-8.

Yoshizawa, K.; Willett, W. C.; Morris, S. J.(1998):

Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. *J. Natl. Inst.*, 90:1219-1224.

Yuan,J.J.;Coplen, D.E.; Petros, J.A.(1992):

Effects of rectal examination ,prostatic massage ,ultrasonography and needle biopsy on serum prostate specific antigen levels.*J.urol.*, 147:810-814.

Zagsbeski ,J. A.(1992):

Physics and instrumentation in Doppler and B-mode ultrasonography. In: Zwiebel ,W.J.eds. *Introduction to vascular ultrasonography*. 3 rd Ed. Philadelphia: WB Saunders,pp:19.

Zalvesky, M. (2003):

Value of power Doppler and 3D vascular sonography as a method for diagnosing prostate cancer. *Eur. Urol.*, 43(2): 124-131.

Zacharias M, Jenderka KV, Heynemann H, Fornara P.(2002):

Transrectal ultrasound of prostate. [Current status and prospects]. *Urologe A*.2002; Nov; 41(6): 559-68.